Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 10, 2016
Event: Announcement of positive topline results from a Phase 2b clinical study for TTP399, a liver-selective glucokinase activator for Type 2 diabetes.
Key Financial Metrics
This filing is a Current Report (Item 8.01) regarding a clinical trial update. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Clinical Results
- Study Name: Phase 2b AGATA (Add Glucokinase Activator to Target A1c).
- Study Design: Six-month, double-blind, placebo- and active-controlled parallel group trial.
- Population: 190 patients with Type 2 diabetes on stable metformin; 110 subjects completed the trial.
- Primary Endpoint: Achieved. Statistically significant change from baseline in HbA1c at 6 months for the 800 mg daily dose of TTP399.
- Key Findings: HbA1c reduction was dose-dependent and sustained. The drug was well-tolerated.
- Specific Cohort: 26 subjects received the full six-month course of the 800 mg dose.
Outlook and Management Commentary
Management indicated that further analysis of the data is ongoing. The positive results support the continued development of TTP399 for the treatment of Type 2 diabetes. No specific financial guidance or forward-looking revenue projections were included in this report.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed statistical data.
- Monitor upcoming filings for the publication of the full clinical study data and peer-reviewed analysis.
- Review the company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not contain financial data.
- Assess the regulatory pathway and timeline for potential Phase 3 trials based on these Phase 2b results.